


## 1. Participant flow



## 2. Baseline characteristics

| Characteristics | Control arm (n=30) |              | Intervention arm (n=30) |              | Total (n=60) |               |
|-----------------|--------------------|--------------|-------------------------|--------------|--------------|---------------|
|                 | N (%)              | Mean (SD)    | N (%)                   | Mean (SD)    | N (%)        | Mean (SD)     |
| Age (years)     |                    | 38.9 (11.66) |                         | 36.6 (10.23) |              | 37.75 (10.94) |

|                                    |           |                 |           |                 |           |                 |
|------------------------------------|-----------|-----------------|-----------|-----------------|-----------|-----------------|
| Gender: female                     | 13 (43.3) |                 | 18 (60.0) |                 | 31 (51.7) |                 |
| <i>Sexual orientation</i>          |           |                 |           |                 |           |                 |
| Heterosexual                       | 19 (63.3) |                 | 25 (83.3) |                 | 44 (73.3) |                 |
| MSM                                | 5 (16.7)  |                 | 3 (10.0)  |                 | 8 (13.3)  |                 |
| WSW                                | 1 (3.3)   |                 | -         |                 | 1 (1.7)   |                 |
| Bisexual                           | 3 (10.0)  |                 | 2 (6.7)   |                 | 5 (8.3)   |                 |
| Missing                            | 2 (6.7)   |                 |           |                 | 2 (3.3)   |                 |
| Has a partner (yes)                | 19 (63.3) |                 | 20 (66.7) |                 | 39 (65.0) |                 |
| Number of children                 |           | 1.37 (1.47)     |           | 2.07 (1.44)     |           | 1.72 (1.49)     |
| Number of financial dependants     |           | 1.24 (1.27)     |           | 2.83 (2.48)     |           | 2.05 (2.12)     |
| <i>Education</i>                   |           |                 |           |                 |           |                 |
| No school                          | 1 (3.3)   |                 | 2 (6.7)   |                 | 3 (5.0)   |                 |
| Primary                            | 2 (6.7)   |                 | 4 (13.3)  |                 | 6 (10.0)  |                 |
| Secondary                          | 7 (23.3)  |                 | 15 (50.0) |                 | 22 (36.7) |                 |
| Diploma                            | 13 (43.3) |                 | 4 (13.3)  |                 | 17 (28.3) |                 |
| ≥Degree                            | 7 (23.3)  |                 | 5 (16.7)  |                 | 12 (20.0) |                 |
| <i>Employment status</i>           |           |                 |           |                 |           |                 |
| White Collar Worker                | 4 (13.3)  |                 | 3 (10.0)  |                 | 7 (11.7)  |                 |
| Shop keepers                       | 15 (50.0) |                 | 20 (66.7) |                 | 35 (58.3) |                 |
| Skilled Worker                     | 1 (3.3)   |                 | -         |                 | 1 (1.7)   |                 |
| Unemployed                         | 9 (30.0)  |                 | 7 (23.3)  |                 | 16 (26.7) |                 |
| Missing                            | 1 (3.3)   |                 | -         |                 | 1 91.7)   |                 |
| CD4 count (cells/mm <sup>3</sup> ) |           | 363.59 (137.31) |           | 366.91 (145.49) |           | 365.12 (139.68) |
| <i>WHO clinical stage</i>          |           |                 |           |                 |           |                 |
| Stage 1                            | 4 (13.3)  |                 | -         |                 | 4 (6.7)   |                 |
| Stage 2                            | 21 (70.0) |                 | 24 (80.0) |                 | 45 (75.0) |                 |
| Stage 3                            | 4 (13.3)  |                 | 4 (13.3)  |                 | 8 (13.3)  |                 |
| Stage 4                            | 1 (3.3)   |                 | -         |                 | 1 (1.7)   |                 |
| Missing                            |           |                 | 2 (6.7)   |                 | 2 (3.3)   |                 |

### 3. Outcome measures

| Control (SHC)          |  |  |  |  |  |  |  | Intervention (CECI)                    |  |   |  |  |  |  |   |
|------------------------|--|--|--|--|--|--|--|--|--|---|--|--|--|--|---|
| Measures               | Baseline<br>(mean<br>(SD) or<br>n (%)) | Time<br>1<br>(mean<br>(SD)<br>or n<br>(%)) | Change<br>score<br>(T1-T0)<br>Mean<br>(SD) | Time<br>2<br>(mean<br>(SD)<br>or n<br>(%)) | Change<br>score<br>(T2-T0)<br>Mean<br>(SD) | Time<br>3<br>(mean<br>(SD)<br>or n<br>(%)) | Change<br>score<br>(T3-T0)<br>Mean<br>(SD) | Baseline<br>(mean<br>(SD) or<br>n (%)) | Time<br>1<br>(mean<br>(SD)<br>or n<br>(%)) | Change<br>score<br>(T1-T0)<br>(mean<br>(SD) | Time<br>2<br>(mean<br>(SD)<br>or n<br>(%)) | Change<br>score<br>(T2-T0)<br>Mean<br>(SD) | Time<br>3<br>(mean<br>(SD)<br>or n<br>(%)) | Change<br>score<br>(T3-T0)<br>Mean<br>(SD) | Potential<br>Effect size<br>[95% CI] of<br>the<br>intervention<br>at Time 3 |
| No. of<br>participants | N=30                                   | N=28                                       |  | N=29                                       |  | N=30                                       |  | N=30                                   | N=28                                       |   | N=30                                       |  | N=28                                       |  |   |
| APCAPOS* <sup>1</sup>  | 12.0<br>(4.1)                          | 13.0<br>(3.8)                              | 1.0<br>(5.6)                               | 16.0<br>(2.0)                              | 4.0<br>(4.6)                               | 14<br>(1.7)                                | 2.0<br>(4.4)                               | 14.0<br>(2.9)                          | 11.0<br>(1.7)                              | -3.0<br>(3.4)                               | 9.0<br>(1.2)                               | -5.0<br>(3.1)                              | 9.0<br>(1.5)                               | -5.0<br>(3.3)                              | 0.7 [0.17 to 1.23]  |
| MOSHIV* <sup>2</sup>   | 30.1<br>(9.2)                          | 25.5<br>(13.6)                             | -4.6<br>(16.42)                            | 19.5<br>(12.2)                             | -10.6<br>(15.3)                            | 53.2<br>(7.8)                              | 23.1<br>(12.1)                             | 26.6<br>(7.5)                          | 66.4<br>(6.5)                              | 39.8<br>(9.9)                               | 74.0<br>(4.0)                              | 47.4<br>(8.5)                              | 83.0<br>(2.9)                              | 56.4<br>(8.0)                              | 0.7 [0.17 to 1.23]  |
| PEQ <sup>2</sup>       | 31.0<br>(1.9)                          | 32.0<br>(2.1)                              | 1.0<br>(2.8)                               | 33.0<br>(1.2)                              | 2.0<br>(2.2)                               | 32.0<br>(1.5)                              | 1.0<br>(2.4)                               | 30.0<br>(2.7)                          | 26.0<br>(1.9)                              | -4.0<br>(3.3)                               | 24.0<br>(2.7)                              | -6.0<br>(3.8)                              | 24.0<br>(2.4)                              | -4.0<br>(3.6)                              | 0.8 [0.27 to  |

<sup>1</sup> Lower scores= better outcomes

<sup>2</sup> Higher scores= better outcomes

\*Some items were reversed

|                          |               |               |               |               |              |               |              |               |               |                |               |               |               |                |                       |
|--------------------------|---------------|---------------|---------------|---------------|--------------|---------------|--------------|---------------|---------------|----------------|---------------|---------------|---------------|----------------|-----------------------|
|                          |               |               |               |               |              |               |              |               |               |                |               |               |               |                | 1.31]                 |
| <b>CAREM<sup>2</sup></b> | 5.0<br>(3.3)  | 3.0<br>(2.8)  | -2.0<br>(4.3) | 5.0<br>(1.1)  | 0.0<br>(3.5) | 7.0<br>(1.6)  | 2.0<br>(3.7) | 5.0<br>(3.3)  | 23.0<br>(3.1) | 18.0<br>(4.5)  | 27.0<br>(2.2) | 22.0<br>(4.0) | 33.0<br>(1.4) | 28.0<br>(3.6)  | 1.0 [0.45 to<br>1.55] |
| <b>PO<sup>2</sup></b>    | 30.0<br>(5.2) | 28.0<br>(6.5) | -2.0<br>(8.3) | 38.0<br>(4.5) | 8.0<br>(6.9) | 30.0<br>(3.9) | 0.0<br>(6.5) | 26.0<br>(8.1) | 23.0<br>(6.0) | -3.0<br>(10.1) | 18.0<br>(3.8) | -8.0<br>(8.9) | 16.0<br>(3.8) | -10.0<br>(8.9) | 0.7 [0.17 to<br>1.23] |

4. There were no adverse events associated with this trial.